Home
About
Overview
Sharing Data
ORCID
Help
History (5)
Co-Principal Investigator
Myeloid-derived suppressor cells as a potential therapy for experimental autoimmune myasthenia gravis.
P2.36: Nivolumab (nivo) in Patients (pts) With Advanced (adv) NSCLC and Central Nervous System (CNS) Metastases (mets): Track: Immunotherapy.
The inherent cellular radiosensitivity of epithelial ovarian carcinoma.
Tracheomediastinal Fistula: Rare Complication of Treatment with Bevacizumab.
See All 5 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Myeloid-derived suppressor cells as a potential therapy for experimental autoimmune myasthenia gravis.
Myeloid-derived suppressor cells as a potential therapy for experimental autoimmune myasthenia gravis. J Immunol. 2014 Sep 01; 193(5):2127-34.
View in:
PubMed
subject areas
Animals
Autoantibodies
B-Lymphocytes
Dinoprostone
Hepatic Stellate Cells
Immunoglobulin G
Immunoglobulin M
Mice
Myasthenia Gravis, Autoimmune, Experimental
Myeloid Cells
Receptors, Nicotinic
T-Lymphocytes
authors with profiles
John Fung